EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
1.14.14.1 | microsome | - |
Homo sapiens | - |
- |
1.14.14.1 | microsome | - |
Rattus norvegicus | - |
- |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.14.14.1 | Homo sapiens | - |
- |
- |
1.14.14.1 | Homo sapiens | P05177 | - |
- |
1.14.14.1 | Rattus norvegicus | P04799 | - |
- |
1.14.14.1 | Rattus norvegicus | P04800 | - |
- |
1.14.14.1 | Rattus norvegicus | P05182 | - |
- |
1.14.14.1 | Rattus norvegicus | P08683 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
1.14.14.1 | hepatocyte | - |
Homo sapiens | - |
1.14.14.1 | hepatocyte | - |
Rattus norvegicus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.14.14.1 | 6beta-hydroxytestosterone + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? | |
1.14.14.1 | 7-ethoxyresorufin + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | ? | - |
? | |
1.14.14.1 | 7-ethoxyresorufin + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? | |
1.14.14.1 | p-nitrophenol + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? | |
1.14.14.1 | p-nitrophenol + [reduced NADPH-hemoprotein reductase] + O2 | CYP2E1 | Homo sapiens | ? | - |
? | |
1.14.14.1 | testosterone + [reduced NADPH-hemoprotein reductase] + O2 | CYP3A4 | Homo sapiens | 6beta-hydroxytestosterone + [oxidized NADPH-hemoprotein reductase] + H2O | - |
? | |
1.14.14.1 | tolbutamide + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? | |
1.14.14.1 | tolbutamide + [reduced NADPH-hemoprotein reductase] + O2 | CYP2C9 | Homo sapiens | ? | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.14.14.1 | CYP1A2 | - |
Homo sapiens |
1.14.14.1 | CYP1A2 | - |
Rattus norvegicus |
1.14.14.1 | CYP2C11 | - |
Rattus norvegicus |
1.14.14.1 | CYP2C9 | - |
Homo sapiens |
1.14.14.1 | CYP2E1 | - |
Homo sapiens |
1.14.14.1 | CYP2E1 | - |
Rattus norvegicus |
1.14.14.1 | CYP3A1 | - |
Rattus norvegicus |
1.14.14.1 | CYP3A4 | - |
Homo sapiens |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
1.14.14.1 | NADPH | - |
Homo sapiens |
EC Number | Organism | Comment | Expression |
---|---|---|---|
1.14.14.1 | Rattus norvegicus | in hepatocyte cultures, treated with 0.05 mM Andrographis paniculata extract and Andrographolide, CYP2E1 is not significantly decreased (by 30%) | down |
1.14.14.1 | Rattus norvegicus | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 50% decrease in CYP3A1 expression and activity | down |
1.14.14.1 | Rattus norvegicus | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 60% decrease in CYP1A2 expression and activity | down |
1.14.14.1 | Rattus norvegicus | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 60% decrease in CYP2C11 expression and activity. After in vivo administration, Andrographis paniculata extract at dose levels of 0.5 g/kg/day (i.e. 5 mg/kg/day Andrographolide equivalents) and at 2.5 g/kg/day (i.e. 25 mg/kg/day Andrographolide equivalents) and Andrographolide at dose levels of 5 and 25 mg/kg/day significantly decrease CYP2C11 activity | down |
1.14.14.1 | Homo sapiens | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract results in a slight decrease of CYP1A2 (30%) enzymatic activities | down |
1.14.14.1 | Homo sapiens | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract results in a slight decrease of CYP2E1 (20%) enzymatic activities, whereas CYP2C9- and CYP3A4-dependent monooxygenase activities are significantly decreased by 40% and 60%, respectively. Andrographolide causes a 30% decrease in CYP2C9- and CYP3A4-dependent monooxygenase activities, which is not significant | down |
1.14.14.1 | Rattus norvegicus | beta-naphthoflavone (0.05 mM) causes a 71fold increase in CYP1A2-dependent activity and a 253fold increase in CYP1A2 mRNA expression in hepatocyte microsomes | up |
1.14.14.1 | Homo sapiens | beta-naphthoflavone (0.05 mM) causes a 9fold increase in CYP1A2-dependent activity and a 25fold increase in CYP1A2 mRNA expression in hepatocyte microsomes | up |
1.14.14.1 | Rattus norvegicus | dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP2C11 activity by a mean of 1.4fold in hepatocytes | up |
1.14.14.1 | Homo sapiens | dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP3A4 mRNA expression by a mean of 14fold in hepatocytes | up |
1.14.14.1 | Rattus norvegicus | dexamethasone (0.05 mM) increases CYP3A1 activity by a mean of 6fold and dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP3A1 mRNA expression by a mean of 167fold in hepatocytes | up |